Drug Trial Radar · NCT03766295
Masitinib Plus Gemcitabine in Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Dec 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
377
Actual
Start
Jul 2014
Primary completion
Dec 2020
Study completion Dec 2020
Sponsor
- Lead sponsor
- AB ScienceIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to compare efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine, in treatment of patients with locally advanced or metastatic pancreatic cancer and who have pain related to the disease.
Conditions
- Locally Advanced or Metastatic Pancreatic Cancer
Interventions
MasitinibDrug
GemcitabineDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (median)Time frame: From day of randomization to death, assessed for a maximum of 60 months
Locations
9 sites in 8 countries. Site status is shown where the registry gives one.
Hospital AZ Sint-Jan
Bruges, Belgium
Polyclinique de Limoges site CHENIEUX
Limoges, France
Centre Hospitalier de Longjumeau
Longjumeau, France
General University Hospital of Patras
Pátrai, Greece
Sanjeevani CBCC USA Cancer Hospital
Raipur, India
Omsk Clinical oncology dispensary Omsk
Omsk, Russia
National Oncology Institute
Bratislava, Slovakia
Institut Salah Azaiez de Cancerologie
Bab Saadoun, Tunisia
Center of Surgical Innovations
Kiev, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.